Genentech: FDA Approves TECENTRIQ To Treat Type Of Metastatic Lung Cancer

(RTTNews) - Genentech, a member of the Roche Group (ROG.SW, RO.SW), announced the U.S. FDA approved TECENTRIQ (atezolizumab) for the treatment of people with metastatic non-small cell lung cancer who have disease progression during or following platinum-containing chemotherapy, and have progressed on an appropriate FDA-approved targeted therapy if their tumor has EGFR or ALK gene abnormalities.

"TECENTRIQ is a new option to help people with this type of previously treated metastatic lung cancer, regardless of PD-L1 expression, live longer than chemotherapy. TECENTRIQ is the first and only approved cancer immunotherapy designed to target the PD-L1 protein, which may play an important role in the way the medicine works," said Sandra Horning, chief medical officer and head of Global Product Development.